Observational studyBMC pulmonary medicine2025
Exploring the role of serum adiponectin and its holigomerization in fibrotic interstitial lung diseases: results from a cross-sectional study.
Observational study in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Next-Generation Sequencing in Pulmonary Fibrosis: Translational Promise and Current Clinical Limitations.Current issues in molecular biology · 2026Review
- Pulmonary Fibrosis Beyond the Lung: Adipose Tissue as a Systemic Modifier of Fibrotic Remodeling.Diagnostics (Basel, Switzerland) · 2026Review
- Role of Airwave Oscillometry in Patients with Combined Fibrosis-Emphysema Syndrome (CPFE) with Preserved FEV1/FVC Ratio.Diagnostics (Basel, Switzerland) · 2026Article
- Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature.Journal of clinical medicine · 2026Review
- Adiponectin and phase angle in the assessment of sarcopenia in Crohn's disease: beyond muscle mass.Frontiers in nutrition · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intestitial lung diseases (ILDs) include a group of inflammatory and fibrotic pulmonary disorders with different etiologies which in several patients might lead to a progressive reduction of respiratory capacities and chronic respiratory failure. Nowadays, biomarkers for predicting the ILD progression and response to therapies are lacking. Adiponectin, the most abundant peptide secreted by adipocytes, has emerged as a potential response biomarker in fibrotic progressive ILDs. The aim of this observational prospective single-center cross-sectional study is therefore to verify whether serum adiponectin levels were altered in patients with fibrotic ILDs (f-ILDs) and its correlation with clinical and pulmonary function data. Sixty-four f-ILDs patients - divided in three subgroups IPF, CTD-ILDs and other f-ILDs - and 45 healthy subjects were recruited. Serum adiponectin concentration were measured by enzyme-linked immunosorbent assay (ELISA). Pulmonary function tests and clinical data were systematically collected. The results showed that patients with f-ILDs have reduced circulating levels of serum adiponectin (12.5 [10.8-15.4] versus 19.3 [17.3-20.8] p < 0.001). No significant difference in adiponectin levels were observed in the different f-ILDs subgroups (p = 0.619). Adiponectin levels were not associated with progression of f-ILDs (p = 0.745). High molecular weight adiponectin isoform was highly reduced in patients with f-ILDs. In patients with CTD-ILDs - but not in other subgroups - adiponectin levels were associated with pulmonary function and GAP index. These resuls support a potential role of adiponectin as diagnostic and prognostic biomarker of f-ILDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.